Human Immunology Biosciences, Inc.
https://www.hibio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Human Immunology Biosciences, Inc.
Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy
Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).
Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal
Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab.
Finance Watch: Three New Funds Bring $1.6bn-Plus For Biopharma Firms Globally
Private Company Edition: TCGX raises $1bn for its second fund, Goldman Sachs’ first fund totals $650m and Panlin’s biopharma fund grows. Also, Apollo’s series C increases to $260m, Avistone closes a $140m series B, OnCusp raises a $100m series A and HI-Bio grabs $95m in series B cash.
Novartis Aims To Fly High In Kidney Disease With Chinook Buy
Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice